1. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
- Author
-
Ken-ichiro Kikuta, Wen Kuang Yang, Toshihiko Kubota, Yin Cheng Huang, Den Mei Yang, Kuo Jen Wei, and Chen Nen Chang
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Cancer Vaccines ,Immunotherapy, Adoptive ,Gastroenterology ,Young Adult ,Antigens, CD ,Physiology (medical) ,Internal medicine ,Glioma ,Glial Fibrillary Acidic Protein ,medicine ,Humans ,Postoperative Period ,Adverse effect ,Survival rate ,Aged ,Brain Neoplasms ,business.industry ,Therapeutic effect ,Dendritic Cells ,General Medicine ,Immunotherapy ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Vaccine therapy ,Surgery ,Vaccination ,Clinical trial ,Treatment Outcome ,Neurology ,Female ,Neurology (clinical) ,business ,Follow-Up Studies - Abstract
Previous clinical trials of dendritic cell (DC)-based immunotherapy in patients with glioblastoma multiforme (GBM) have reported induction of systemic immune responses and prolonged survival. From 2003 to 2005, we performed a clinical trial in which patients with malignant glioma underwent surgery for maximal cytoreduction followed by a 6-month 10-injection course of autologous DC-tumor vaccine therapy, each injection containing 1-6×10(7) DC. Of the 17 treated patients (16 with World Health Organization grade IV and one with grade III glioma), eight (47.1%) had an initial transient elevation in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). Vaccination caused some tumor shrinkage and increased concentration of tumor-infiltrating CD8(+) lymphocytes. Median survival and 5-year survival were 525 days and 18.8%, respectively, for 16 patients with grade IV glioma (381 days and 12.5% for eight newly diagnosed; 966 days and 25% for eight relapsed patients) compared to 380 days and 0% for 63 historical control patients. We concluded that autologous DC-tumor immunotherapy benefits patients with malignant glioma but may cause transient but reversible elevation of serum AST/ALT levels.
- Published
- 2011
- Full Text
- View/download PDF